Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.
A group of Quintiles shareholders including the CRO's founder made about $770 million in a secondary stock offering, selling a bulk of shares back to the company and cashing in on its success.
Awaiting the closure of a wide-ranging deal with Quest Diagnostics, Quintiles is expanding its capabilities in bioanalytics, opening a new outpost in Europe for lab tests.
Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance.
Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.
Months after LabCorp acquired its rival Covance, Quintiles has signed a sweeping agreement with lab testing giant Quest Diagnostics to launch a joint venture focused on clinical trials.
Quest Diagnostics is forming a joint venture with global CRO Quintiles to provide laboratory services for clinical trials, lending its research and diagnostic know-how to biopharma partners with precision medicine initiatives.
Quest Diagnostics is partnering with contract research organization Quintiles to create a joint venture to provide a range of clinical trial services to biopharmas including laboratory testing and patient recruitment and retention as well as development and commercialization of companion diagnostics.
Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.
Global CRO Quintiles is planning to lay off about 270 workers, 1% of its payroll, in an effort to reduce "excess capacity," the company said.